{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:23:04Z","timestamp":1762878184843,"version":"3.45.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"special clinic project of Shanghai","award":["20234Y0264"],"award-info":[{"award-number":["20234Y0264"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03836-x","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:35:45Z","timestamp":1762875345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report of curative resection after preoperative bevacizumab and sintilimab therapy in hepatocellular carcinoma with lymph node metastasis"],"prefix":"10.1007","volume":"16","author":[{"given":"Shujie","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"10360","key":"3836_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"3836_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatol. 2021;73(Suppl 1):4\u201313.","journal-title":"Hepatol"},{"issue":"5","key":"3836_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14737140.2025.2489651","volume":"25","author":"QB Wang","year":"2025","unstructured":"Wang QB, Li J, Zhang ZJ, Li YK, Liang YB, Chen XM, et al. The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior Vena cave and\/or right atrium: a systematic review and single-arm meta-analysis. Expert Rev Anticancer Ther. 2025;25(5):561\u201370.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"3836_CR4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"20","key":"3836_CR5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"7","key":"3836_CR6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3836_CR7","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1093\/oncolo\/oyad083","volume":"28","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li Q, Zhang L, Liu S, Zhu J, Yang Y, et al. Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma. Oncologist. 2023;28(6):e369\u201378.","journal-title":"Oncologist"},{"key":"3836_CR8","doi-asserted-by":"crossref","first-page":"835957","DOI":"10.3389\/fonc.2022.835957","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Lu Y, Shi X, Han G, Zhao J, Gao Y, et al. Development and validation of a novel model to predict regional lymph node metastasis in patients with hepatocellular carcinoma. Front Oncol. 2022;12:835957.","journal-title":"Front Oncol"},{"key":"3836_CR9","doi-asserted-by":"crossref","first-page":"1519999","DOI":"10.3389\/fimmu.2024.1519999","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Liang YB, Wang QB, Li YK, Chen XM, Luo WL, et al. Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: A systematic review and meta-analysis. Front Immunol. 2024;15:1519999.","journal-title":"Front Immunol"},{"issue":"4","key":"3836_CR10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1440-1746.2006.04450.x","volume":"22","author":"H Yamashita","year":"2007","unstructured":"Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, et al. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol. 2007;22(4):523\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3836_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/liv.15051","volume":"42","author":"HY Woo","year":"2022","unstructured":"Woo HY, Rhee H, Yoo JE, Kim SH, Choi GH, Kim DY, et al. Lung and lymph node metastases from hepatocellular carcinoma: comparison of pathological aspects. Liver Int: Off J Int Assoc Study Liver. 2022;42(1):199\u2013209.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"issue":"4","key":"3836_CR12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452\u201363.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"3836_CR13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1148\/radiol.2016151807","volume":"282","author":"T Pan","year":"2017","unstructured":"Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis. Radiology. 2017;282(1):259\u201370.","journal-title":"Radiology"},{"issue":"1","key":"3836_CR14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"3836_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/17474124.2015.959929","volume":"9","author":"MN Kim","year":"2015","unstructured":"Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9(3):335\u201348.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"27","key":"3836_CR16","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus Sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39(27):3002\u201311.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"3836_CR17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.suronc.2020.12.011","volume":"36","author":"PM Kemp Bohan","year":"2021","unstructured":"Kemp Bohan PM, O\u2019Shea AE, Lee AJ, Chick RC, Newhook TE, Tran Cao HS, et al. Lymph node sampling in resectable hepatocellular carcinoma: National practice patterns and predictors of positive lymph nodes. Surg Oncol. 2021;36:138\u201346.","journal-title":"Surg Oncol"},{"issue":"4","key":"3836_CR18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jso.24908","volume":"117","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Frankel TL, Sonnenday C, Cho CS, Nathan H. Critical evaluation of the American joint commission on cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): a surveillance, epidemiology, end results (SEER) analysis. J Surg Oncol. 2018;117(4):644\u201350.","journal-title":"J Surg Oncol"},{"issue":"4","key":"3836_CR19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835\u201353.","journal-title":"Gastroenterology"},{"issue":"3","key":"3836_CR20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000529201","volume":"12","author":"BM Lee","year":"2023","unstructured":"Lee BM, Choi JY, Seong J. Efficacy of local treatment in lymph node metastasis from hepatocellular carcinoma. Liver Cancer. 2023;12(3):218\u201328.","journal-title":"Liver Cancer"},{"issue":"4","key":"3836_CR21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00534-011-0372-y","volume":"18","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Takahashi S, Kato Y, Gotohda N, Nakagohri T, Konishi M, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepato-biliary-pancreat Sci. 2011;18(4):559\u201366.","journal-title":"J Hepato-biliary-pancreat Sci"},{"issue":"2","key":"3836_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1015-9584(11)60020-1","volume":"34","author":"CW Lee","year":"2011","unstructured":"Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, Wu TJ, et al. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg. 2011;34(2):53\u201362.","journal-title":"Asian J Surg"},{"issue":"3","key":"3836_CR23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant Cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3836_CR24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3836_CR25","doi-asserted-by":"crossref","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J ImmunoTher Cancer. 2022;10(4):e004656.","journal-title":"J ImmunoTher Cancer"},{"key":"3836_CR26","doi-asserted-by":"crossref","first-page":"1163656","DOI":"10.3389\/fimmu.2023.1163656","volume":"14","author":"H Deng","year":"2023","unstructured":"Deng H, Chen B, Peng D, He J, Zhao W, Chen T, et al. Case report: complete response after Tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis. Front Immunol. 2023;14:1163656.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:35:48Z","timestamp":1762875348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3836"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03836-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted according to the Declaration of Helsinki. This work was approved by the Institutional Review Board of the Eastern Hepatobiliary Surgery Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the journal\u2019s policies and submitted their manuscripts in accordance with these policies. All authors agree with the content of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2088"}}